格卡瑞韦-哌仑他韦治疗丙肝的简化监测随机非劣效试验
这项开放标签多中心IIIb期随机试验纳入380例无肝硬化初治慢性丙肝患者,按2:1接受格卡瑞韦-哌仑他韦300mg-120mg每日一次治疗8周,比较简化监测与标准监测。意向治疗人群中简化组SVR12为92%,标准组为95%,差异-3.2%(95%CI -8.2%至1.8%),未达到6%非劣效界值。
要点
- 8周格卡瑞韦-哌仑他韦治疗无肝硬化慢性丙肝安全有效。
- 简化监测组SVR12为92%,标准监测组为95%,未达非劣效。
- 意向治疗人群差异-3.2%(95%CI -8.2%至1.8%),非劣效界值6%。
核心结论
- 在无肝硬化慢性HCV感染患者中,格卡瑞韦-哌仑他韦治疗安全有效。
- 与标准监测相比,简化监测方案未达到非劣效性。
研究设计与样本
- 开放标签多中心IIIb期随机非劣效试验,纳入无肝硬化初治慢性HCV成人,按2:1随机分配。
- 简化监测组253例,标准监测组127例,均接受格卡瑞韦-哌仑他韦300mg-120mg每日一次治疗8周。
主要发现
- 意向治疗人群SVR12:简化组92%(95%CI 89%-95%),标准组95%(95%CI 92%-99%)。
- 两组差异-3.2%(95%CI -8.2%至1.8%),未达到6%非劣效界值。
- 符合方案人群SVR12:简化组97%(95%CI 96%-99%),标准组98%(95%CI 96%-100%)。
- 未报告治疗相关严重不良事件。
关键数值与推荐
- 主要终点为治疗后第12周持续病毒学应答(SVR12),非劣效界值为6%。
- 简化监测组仅基线和治疗后第12周门诊访视,标准监测组增加第4周和第8周访视,两组第4周和第8周均有护士电话联系。
临床怎么用
- 对于无肝硬化慢性丙肝初治患者,格卡瑞韦-哌仑他韦8周方案安全有效。
- 简化监测策略虽治愈率高,但未证明非劣效于标准监测,临床选择监测方案时需考虑此结果。
局限性
- 研究排除了需要依从性支持的患者,包括近期注射吸毒者。
- 开放标签设计可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule. METHODS: In this open-label multicentre phase IIIb trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks administered with a simplified or standard monitoring strategy. Clinic visits occurred at baseline and post-treatment week 12 in the simplified arm, and at baseline, week 4, week 8, and post-treatment week 12 in the standard arm. Study nurse phone contact occurred at week 4 and week 8 in both arms. Participants requiring adherence support were not eligible, including those reporting recent injecting drug use. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12), with a non-inferiority margin of 6%. RESULTS: Overall, 380 participants (60% male, 47% genotype 1, 32% genotype 3) with chronic HCV were randomised and treated with glecaprevir-pibrentasvir in the simplified (n = 253) and standard (n = 127) arms. In the intention-to-treat population, SVR12 was 92% (95% CI 89%-95%) in the simplified and 95% (95% CI 92%-99%) in the standard arm (difference between arms -3.2%; 95% CI -8.2% to 1.8%) and did not reach non-inferiority. In the per-protocol population, SVR12 was 97% (95% CI 96%-99%) in the simplified and 98% (95% CI 96%-100%) in the standard arm. No treatment-related serious adverse events were reported. CONCLUSIONS: In patients with chronic HCV infection without cirrhosis, treatment with glecaprevir-pibrentasvir was safe and effective. In comparison to standard monitoring, a simplified monitoring schedule did not achieve non-inferiority. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT03117569. LAY SUMMARY: Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an 8-week regimen of glecaprevir-pibrentasvir for hepatitis C treatment, using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but this was not equivalent to the standard monitoring schedule cure rate (95%).
引用
- Dore GJ, Feld JJ, Thompson A, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2019. PMID: 31655134. doi:10.1016/j.jhep.2019.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。